Janus kinase–signal transducers and activators of transcription cell signaling in Spondyloarthritis: rationale and evidence for JAK inhibition
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Janus kinase–signal transducers and activators of transcription cell signaling in Spondyloarthritis: rationale and evidence for JAK inhibition
Authors
Keywords
-
Journal
CURRENT OPINION IN RHEUMATOLOGY
Volume 33, Issue 4, Pages 348-355
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2021-05-21
DOI
10.1097/bor.0000000000000810
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis
- (2020) Alexandre Sepriano et al. ANNALS OF THE RHEUMATIC DISEASES
- TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis
- (2020) Eric Gracey et al. JOURNAL OF CLINICAL INVESTIGATION
- Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
- (2020) Philip Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- SnapShot: Jak-STAT Signaling II
- (2020) Alejandro V. Villarino et al. CELL
- Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases
- (2020) Brian S Gerstenberger et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
- (2020) Peter Nash et al. Rheumatology and Therapy
- Janus kinases to jakinibs: from basic insights to clinical practice
- (2019) Massimo Gadina et al. RHEUMATOLOGY
- Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases
- (2019) Anniina T. Virtanen et al. BIODRUGS
- Pharmacology, efficacy and safety of JAK inhibitors in Crohn’s disease
- (2019) Christopher Ma et al. BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY
- Studying interactions between dendritic cells and T cells in vivo
- (2019) Aleksey Chudnovskiy et al. CURRENT OPINION IN IMMUNOLOGY
- Polyfunctional TEM cells in psoriatic arthritis synovium skewed towards Th17 cells
- (2019) Smriti K Raychaudhuri et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial
- (2019) Désirée van der Heijde et al. LANCET
- Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study
- (2018) Bruce E Sands et al. Journal of Crohns & Colitis
- Benefit-risk of tofacitinib in patients with moderate to severe chronic plaque psoriasis: Pooled analysis across 6 clinical trials
- (2018) B.E. Strober et al. BRITISH JOURNAL OF DERMATOLOGY
- IL-9 receptor: Regulatory role on FLS and pannus formation
- (2018) Smriti K. Raychaudhuri et al. CYTOKINE
- Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
- (2018) Josef S. Smolen et al. JOURNAL OF RHEUMATOLOGY
- Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
- (2018) Kim Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibiting ex-vivo Th17 responses in Ankylosing Spondylitis by targeting Janus kinases
- (2018) Ariane Hammitzsch et al. Scientific Reports
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial
- (2018) Désirée van der Heijde et al. LANCET
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
- (2018) Philip Mease et al. LANCET
- Herpes Zoster in Tofacitinib: Risk is Further Increased with Glucocorticoids but not Methotrexate
- (2018) Jeffrey R Curtis et al. ARTHRITIS CARE & RESEARCH
- Comparative risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors: A cohort study of rheumatoid arthritis patients
- (2018) Rishi J. Desai et al. Arthritis & Rheumatology
- Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
- (2017) Julian Panés et al. GUT
- Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
- (2017) Philip Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis
- (2016) Jeffrey R Curtis et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- IL-23/IL-17 axis in spondyloarthritis-bench to bedside
- (2016) Siba P. Raychaudhuri et al. CLINICAL RHEUMATOLOGY
- IL-9, a local growth factor for synovial T cells in inflammatory arthritis
- (2016) Smriti Kundu-Raychaudhuri et al. CYTOKINE
- Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity
- (2016) C. A. Dendrou et al. Science Translational Medicine
- Review: Enthesitis: New Insights Into Pathogenesis, Diagnostic Modalities, and Treatment
- (2016) Amy S. Kehl et al. Arthritis & Rheumatology
- Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors
- (2015) W Gao et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
- (2015) Jeffrey R Curtis et al. ANNALS OF THE RHEUMATIC DISEASES
- Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
- (2014) James D. Clark et al. JOURNAL OF MEDICINAL CHEMISTRY
- Combined Analysis of Genome-wide Association Studies for Crohn Disease and Psoriasis Identifies Seven Shared Susceptibility Loci
- (2012) David Ellinghaus et al. AMERICAN JOURNAL OF HUMAN GENETICS
- U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis
- (2012) A. Deisseroth et al. CLINICAL CANCER RESEARCH
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Podoplanin expression in wound and hyperproliferative psoriatic epidermis: Regulation by TGF-β and STAT-3 activating cytokines, IFN-γ, IL-6, and IL-22
- (2011) Masaru Honma et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Analysis of JAK2 and STAT3 polymorphisms in patients with ankylosing spondylitis in Chinese Han population
- (2010) Chao Chen et al. CLINICAL IMMUNOLOGY
- Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
- (2010) Debra M Meyer et al. Journal of Inflammation-London
- Genetic factors in chronic inflammation: Single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population
- (2010) Lynnette R. Ferguson et al. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now